Unique ID issued by UMIN | UMIN000006576 |
---|---|
Receipt number | R000007266 |
Scientific Title | The Impact of MMF dosing on Donor specific Anti-HLA antibodies in the clinical management of kidney transplant recipient |
Date of disclosure of the study information | 2011/12/01 |
Last modified on | 2014/12/26 16:52:49 |
The Impact of MMF dosing on Donor specific Anti-HLA antibodies
in the clinical management of kidney transplant recipient
The Impact of MMF dosing on Donor specific Anti-HLA antibodies
in the clinical management of kidney transplant recipient
The Impact of MMF dosing on Donor specific Anti-HLA antibodies
in the clinical management of kidney transplant recipient
The Impact of MMF dosing on Donor specific Anti-HLA antibodies
in the clinical management of kidney transplant recipient
Japan |
kidney transplant recipients
Surgery in general |
Others
NO
MMF dose influence on production of anti-HLA antibodies after kidney transplantation
Efficacy
anti-HLA antibodies
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
Control:
Continue rencent immunosuppresive therapy
Study:
In case of under MMF daily dosage 1000mg,increasing 1500mg/day at first and final target dose at 2000mg/day
In case of MMF daily dose from 1000mg to 1500mg, increasing MMF at target dose 2000mg/day
20 | years-old | <= |
Not applicable |
Male and Female
1. Subject inpatient or outpatient to participating hospitals
2. Subject recieved kidney transplantation within 1-5 years
3. Subject recieved MMF under 1500mg daily
4.Subject age under 20 y.o
5. Provision of written informed concent by subject
1.Inablity or un willingness to provide written informed concent
2.Subject under 20 y.o
3.ABO blood type incombatibility kidney transplantation
4. Inable to outpatient treatment in study period
5.Pregnancy or possible to pregnant
6.Nursing
7.Serious digestive disease
8.hypoalbuminemia(2g/dl)
9.low WBC (3000/mm2)
10. Active infectious disease
11. Cancer
12.Recieved live vaccine within 3 month
13. Hypersensitity to MMF
14.Inablity or un willingness to comply with the requirements of the protocol by investigator
300
1st name | |
Middle name | |
Last name | Kazunari Tanabe |
Tokyo Women's Medical University
Urology Unit
8-1 Kawada cho, Sinjyuku ku Tokyo
03-3353-8111
1st name | |
Middle name | |
Last name | Miyuki Furusawa, Hideki Ishida |
Tokyo Women's Medical University
Urology Unit
8-1 Kawada cho, Sinjyuku ku Tokyo
03-3358-0166
Tokyo Women's Medical University
Tokyo Women's Medical University
Self funding
Japan
Ohkubo Hospital, Toda chuo general hospital, Yocho-machi clinic
No
NO
・大久保病院 移植外科
・戸田中央総合病院 泌尿器科
・余丁町クリニック
その他
2011 | Year | 12 | Month | 01 | Day |
Unpublished
Completed
2011 | Year | 11 | Month | 30 | Day |
2011 | Year | 12 | Month | 01 | Day |
2013 | Year | 04 | Month | 01 | Day |
2013 | Year | 06 | Month | 01 | Day |
2013 | Year | 06 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2011 | Year | 10 | Month | 19 | Day |
2014 | Year | 12 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007266
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |